

News Releases

All Years

Search

Go

[Advanced Search](#)

OCT 20, 2022

Inhibrx Announces Participation in Upcoming Scientific Conferences

AUG 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

AUG 8, 2022

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

JUN 30, 2022

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance

MAY 19, 2022

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting

MAY 9, 2022

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

MAR 24, 2022

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

FEB 28, 2022

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

FEB 22, 2022

Inhibrx Announces Amended Loan Agreement with Oxford

JAN 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

Show per
page

«	1	2	3	4	5	6	7	8	»
---	-------------------	-------------------	-------------------	-------------------	---	-------------------	-------------------	-------------------	---



<https://inhibrxbiosciences.investorroom.com/news-releases?l=10&o=40>